Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Work In Process (2020 - 2025)

Puma Biotechnology's Work In Process history spans 6 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Work In Process rose 77.18% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 77.18%, while the annual FY2025 figure was $1.3 million, 77.18% up from the prior year.
  • Work In Process reached $1.3 million in Q4 2025 per PBYI's latest filing, down from $5.4 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $7.8 million in Q2 2024 to a low of $758000.0 in Q4 2024.
  • Average Work In Process over 5 years is $2.5 million, with a median of $2.0 million recorded in 2024.
  • The largest YoY upside for Work In Process was 169.08% in 2025 against a maximum downside of 82.89% in 2025.
  • A 5-year view of Work In Process shows it stood at $1.4 million in 2021, then surged by 92.13% to $2.7 million in 2022, then tumbled by 69.18% to $820000.0 in 2023, then decreased by 7.56% to $758000.0 in 2024, then surged by 77.18% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Work In Process are $1.3 million (Q4 2025), $5.4 million (Q3 2025), and $1.3 million (Q2 2025).